July 8th 2024
A statistically significant and clinically meaningful improvement in progression-free survival in the phase 3 trial DUO-E support the recommendation.
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Pembrolizumab Yields Lasting Anti-Tumor Activity in MSI-H, dMMR Advanced Endometrial Cancer
September 19th 2022Long-term follow-up from the phase 2 KEYNOTE-158 trial showed enduring anti-tumor activity when pembrolizumab was used to treat patients with microsatellite instability–high/mismatch repair deficient advanced endometrial cancer.
ddPCR Analysis Effective in Identifying POLE Mutations in Endometrial Cancer, Study Finds
July 22nd 2022Investigators recommended that ddPCR testing and immunohistochemical staining be used to detect POLE status and p53/mismatch repair status, respectively, and allow for more rapid classification and risk-stratification.
Endometriosis/Adenomyosis Status Not an Independent Predictor of Survival in Endometrial Cancer
April 9th 2022Although patients with endometrial cancer who had histologically confirmed endometriosis/adenomyosis achieved better overall survival than those without, the benefit was linked to stage, grade, age, and histological subtype.